Predictive Oncology Inc. (POAI): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at a company, Predictive Oncology Inc. (POAI), right in the thick of the AI pharma gold rush, and figuring out how they translate that complex Helomics AI platform into real revenue is defintely the key question for any serious investor now. We see a clear strategy: selling high-value Contract Research Organization (CRO) services, often costing clients $150,000 to over $1,000,000 per major engagement, through a direct sales force targeting US and EU biotechs. They back this up with peer-reviewed science and thought leadership promotion, making sure their high-touch, customized pricing model sticks. It's a focused play on precision medicine, and you need to see the details below to map your next move. That's the whole game right there.

Predictive Oncology Inc. (POAI) - Marketing Mix: Product

The product element for Predictive Oncology Inc. centers on its integrated digital biology and laboratory services designed to accelerate oncologic drug discovery and enable personalized treatment development. The core offering leverages proprietary artificial intelligence and machine learning capabilities against an extensive biorepository of tumor samples.

The company's product portfolio is built around several synergistic assets, including the AI platform, specialized testing assays, and contract research capabilities. As of the end of the second quarter of 2025, the company reported total revenue of only $2,682 for that quarter, though the trailing 12-month revenue as of September 30, 2025, reached $1.66M.

The foundation of the product suite is the company's vast biobank, which contains over 150,000 patient tumor samples, including ovarian, head and neck, colon, and pancreas tumors. This biobank feeds the predictive engine.

The key product components and associated metrics are detailed below:

Helomics AI platform for drug response prediction and discovery.

The proprietary artificial intelligence and machine learning platform, referred to as PeDAL, uses historical drug-response data and the tumor sample biobank to generate drug-tumor pairing predictions. This process is iterative, with wet-lab testing results informing subsequent rounds of AI predictions until stabilization occurs.

Focus on leveraging AI to reduce drug development timelines.

The efficiency gains from the AI platform are quantifiable in preclinical stages. In one evaluation using 21 novel compounds, the predictive machine learning model was capable of making confident predictions to cover a total of 73% of all experiments after measuring only 7% of the possible wet lab experiments. This capability is stated to virtually eliminate up to two years of laboratory testing time.

TumorGraft models for personalized oncology research.

The product line includes advanced in vitro models that mimic the complex human organ microenvironment, aiming for high correlation with clinical response. These 3D organoid models substantially complement the AI-driven 2D platform and 3D spheroids. The company also developed predictive models derived from 21 unique compounds from the University of Michigan's Natural Products Discovery Core.

Soluble Therapeutics for protein formulation and stability services.

Assets acquired through Soluble Therapeutics expand capabilities to provide services for the pharmaceutical and biotech industries. This includes predicting and providing the best formulation with the highest concentration and most stable solution for protein and peptide-based drugs.

Contract Research Organization (CRO) services for preclinical testing.

Predictive Oncology Inc. provides custom assay development and contract research services to partners. The Birmingham segment focuses on contract services, including solubility improvements, stability studies, and protein production, offering optimized formulations for vaccines, antibodies, and other protein therapeutics. The company reported a loss from continuing operations of approximately $2.3 million in Q1 2025 on total revenue of $110,310.

The product offerings can be summarized by their application focus:

• AI-driven drug discovery and repurposing.
• Personalized cancer therapy through ChemoFx® testing.
• Custom 3D organoid model development for toxicity studies.
• Protein formulation and stability services.

Predictive Oncology Inc. (POAI) - Marketing Mix: Place

The Place strategy for Predictive Oncology Inc. (POAI) centers on making its AI-driven oncology services and platform accessible to key decision-makers and research entities, primarily through direct engagement and strategic channel expansion.

Direct sales force targeting pharmaceutical and biotech companies. While specific sales force headcount isn't public, the focus is clearly on direct engagement with industry partners. The company expects to progress business development opportunities with leading biopharmaceutical companies. This direct channel focus is supported by a strategic cost management effort, as sales and marketing expenses saw a significant reduction, dropping to $3,633 in the first quarter of 2025, down from $608,710 in the comparable period of 2024.

Academic and institutional research collaborations for platform validation. Distribution of validation and credibility is heavily reliant on academic and institutional partnerships. Predictive Oncology offers its AI-based drug discovery solutions to its academic and industry partners. The company has a history of launching programs, such as the ACE program, to partner with academic and research institutions.

Global reach for services, primarily focused on the US and EU markets. Service availability is being actively expanded across major regulated markets. Predictive Oncology announced a planned European launch of its validated flagship live cell ChemoFx® drug response assay, alongside expanded availability in the United States. The initial focus for this assay is ovarian and other gynecological cancers.

Online access and data delivery through the Helomics platform interface. The core technology delivery mechanism involves the Helomics platform, which applies artificial intelligence to the company's extensive biobank data. The PEDAL AI platform itself is a key component of the solution offered to partners.

Strategic partnerships with other technology providers for expanded service offerings. Distribution and capability expansion are achieved through specific, targeted alliances that enhance the service footprint. The company has also expanded its business to include active digital asset management, creating a Strategic Compute Reserve focused on the Aethir (ATH) token, aiming to monetize AI infrastructure through enterprise deployments.

Here's a quick look at the scale of the assets supporting the distribution of their predictive capabilities:

The distribution of research and validation efforts is channeled through several key relationships:

• Collaboration with Every Cure for drug repurposing initiatives.
• Agreement with Interpace Diagnostics Group Inc. (IDXG) for thyroid cancer products.
• Partnership with Tecn Group Ltd. for High-Throughput Drug Screening expansion.
• Research collaboration with the University of Pittsburgh School of Medicine.
• Collaboration with ChemImage for prostate cancer diagnosis.

The company's focus on core AI/ML capabilities, following the sale of its Skyline Medical assets to DeRoyal Industries, sharpens its Place strategy toward high-value, direct-to-partner service delivery.

Predictive Oncology Inc. (POAI) - Marketing Mix: Promotion

You're looking at how Predictive Oncology Inc. (POAI) gets its message out, which is a mix of hard science communication and high-stakes financial signaling, especially given their recent strategic pivot. Promotion for POAI isn't just about ads; it's about validating their core technology and managing market perception around their new digital asset strategy.

Presentation of scientific data at major oncology and AI conferences.

While specific 2025 conference presentation titles aren't detailed in the latest filings, the company's promotional foundation rests on the scientific validation of its PeDAL™ platform. This platform, which pairs AI with their biobank, is promoted as being able to predict if a tumor sample will respond to a certain drug compound with 92% accuracy. This metric is key for any scientific presentation aimed at biopharma partners. You should expect their scientific teams to be actively presenting data supporting this accuracy at relevant industry gatherings, even if the specific event names aren't in the latest press releases.

Peer-reviewed publications validating the Helomics platform's predictive power.

The scientific credibility of Predictive Oncology Inc. is tied to the validation of its AI platform, which utilizes a biobank of more than 150,000 assay-capable heterogeneous human tumor samples. While I don't have a count of new peer-reviewed publications from late 2025, the ongoing promotion relies on the established scientific rigor of this platform to convince partners of its value in expediting drug discovery.

Investor relations and press releases to communicate strategic milestones.

Investor relations activity has been intense in late 2025, focusing heavily on communicating the digital asset treasury strategy. The company issued a press release on November 14, 2025, reporting Third Quarter 2025 Financial Results and providing that strategic update via a webcast on November 17, 2025. A major milestone communicated was the closing of two private investment in public equity transactions (PIPEs) on October 7, 2025, totaling approximately $343.5 million. This funding included $50.8 million in cash proceeds and approximately $292.7 million in notional value of in-kind contributions of ATH tokens. Furthermore, the communication around regaining compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000 on December 1, 2025, is a critical promotional effort aimed at preserving investor confidence.

Here's a quick look at some of the key financial and operational metrics communicated through these investor releases:

Direct-to-client outreach via the specialized sales and scientific teams.

Direct outreach is centered on promoting the core drug discovery services. This involves the specialized teams engaging academic and industry partners to utilize the PeDAL™ platform and the CLIA laboratory facility. While I don't have specific sales team headcount or outreach metrics for 2025, the focus is clearly on driving adoption of their AI-based drug discovery solutions.

Digital marketing focused on thought leadership in precision medicine.

The digital promotion strategy appears to be heavily weighted toward signaling strategic direction and leadership capability, rather than broad product advertising. The appointments in October 2025, such as Thomas McLaughlin as Chief Investment Officer, are used to communicate expertise in deploying the digital asset strategy. The operating expenses dedicated to sales and marketing were reported as $133,000 for the third quarter of 2025, up from $73,000 for the corresponding quarter in 2024. This increased spend suggests a ramp-up in promotional activities, likely supporting the new digital asset focus and the ongoing promotion of the ChemoFx® assay expansion.

Key promotional activities and associated spend/metrics include:

• Operating expenses to sales and marketing for Q3 2025: $133,000.
• Increase in sales and marketing spend from Q3 2024: $60,000 increase ($133,000 vs $73,000).
• Strategic collaboration announced with Every Cure to identify drugs for repurposing.
• Continued advancement of ChemoFx®, the validated flagship live cell drug response assay, for market expansion in the U.S. and Europe.

Finance: review the Q4 2025 Sales & Marketing budget against the Q3 actuals by next Tuesday.

Predictive Oncology Inc. (POAI) - Marketing Mix: Price

You're looking at how Predictive Oncology Inc. (POAI) prices its specialized services and platform access as of late 2025. Honestly, for a company focused on AI-driven drug discovery, the pricing structure isn't a simple sticker price; it's deeply tied to the complexity of the research and the value of the data access you need.

The core of their revenue generation, based on what they've disclosed, flows through several distinct channels, reflecting the high-value, bespoke nature of their work. You see this reflected in their reported operating revenue, which for the third quarter ended September 30, 2025, was just $3,618. That's a stark contrast to the $67,255 in revenue reported for Q2 2024, showing the lumpy, project-dependent nature of their recognized income.

Here's how the pricing models are structured, at least conceptually:

• Fee-for-service model for specific contract research projects.
• Subscription or licensing fees for access to the Helomics AI platform data.
• Milestone-based payments in co-development or partnership agreements.

Project costs typically range from $150,000 to over $1,000,000 per major engagement. Pricing structure is highly customized based on scope and data volume.

To give you a clearer picture of the financial environment surrounding these pricing activities, here's a snapshot of their recent performance metrics. Remember, these are the outcomes of their pricing strategy, not the rates themselves:

The Helomics AI platform, which leverages a biobank of over 150,000 tumor samples, is central to generating the value that underpins these custom prices. The PEDAL platform, for instance, is cited as achieving 92% accuracy in predicting tumor responses, which is the core deliverable justifying the high-end project costs.

Finance: draft 13-week cash view by Friday.